mastoparan suppressed phosphoinositide hydrolysis induced by muscarinic receptor agonist, carbachol in 1321N1 human astrocytoma cells (Nakahata et al., 1990) . Likewise, Wojcikiewica and Nahorki (1989) showed that mastoparan inhibited phosphoinositide hydrolysis induced by GTPγS in permeabilized SH-SY5Y human neuroblastoma cells. It is difficult to explain that inhibitory effect of mastoparan on phosphoiositide hydrolysis is mediated by its activation of G i/o . Therefore, it seems likely that there is another mechanism of mastoparan-induced inhibition of phosphoinositide hydrolysis besides the activation of G i/o .
Since mastoparan affects various of G-protein-coupled receptor signaling, mastoparan may not be a receptor antagonist. In addition, the suppression of phosphoinositide hydrolysis by mastoparan suggests that the site of action is upstream of phospholipase C. On the other hand, it has been reported that the expression level of sphingoglycolipids affects the composition of lipid rafts, and changes signal transduction (Nishio et al., 2004) . Thus, it is assumed that lipid rafts are important as a place for the regulation of signal transduction.
Furthermore, recent investigations have revealed that a number of pathogens (microorganisms, parasites and virus) and toxins take advantage of lipid rafts as infection routes owing to enrichment of their receptor molecules. For instance, cholera toxin and melittin are associated with GM1 (Chatterjee and Mukhopadhyay, 2002) and vibrio cholerae cytolysin requires sphingoglycolipids and cholesterol for its polymerization (Zitzer et al., 1999) .
In the present study, therefore, we investigated whether mastoparan affected phosphoinositide hydrolysis by interacting with lipid rafts. The results obtained suggest that mastoparan initially binds to gangliosides, especially GD1b and GT1b on cell surface, and then inhibits phosphoinositide hydrolysis by changing the localization of Gα q/11 and Gβ in lipid rafts.
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Materials and Methods
Materials. Mastoparan (Ile-Asn-Leu-Lys-Ala-Leu-Ala-Ala-Leu-Ala-Lys-Lys-Ile-Leu-NH 2 ) was obtained from Peptide Institute Inc. (Osaka, Japan). [Tyr 3 ]Mastoparan (Ile-Asn-TyrLys-Ala-Leu-Ala-Ala-Leu-Ala-Lys-Lys-Ile-Leu-NH 2 ) was synthesized by a peptide synthesizer. Dulbecco's modified Eagle's medium (DMEM) was purchased from Nissui Pharmaceuticals (Tokyo, Japan). GM1 and GQ1b were from Calbiochem (Darmstadt, Germany). GD1a and GD1b were from Toyobo (Osaka, Japan). Uridine 5'-triphosphate (UTP), sialic acid, ganglioside mixtures, GT1b, asialoganglioside-GM1 and neuraminidase type were from Sigma (St. Louis, MO). Lactate dehydrogenase C -test and cholesterol E-test were from Wako Pure Chemicals (Osaka, Japan). [1, [2] [3] H]Myo-inositol was from American Radiolabeled Chemicals (St. Louis, MO). Fura 2-AM was from Dojindo Laboratories (Kumamoto, Japan).
Pertussis toxin (PTX) was from Funakoshi Pharmaceutical (Tokyo, Japan). Other chemicals and drugs were of regent grade or of the highest quality available.
Cell Culture. PC12 cells were grown in DMEM containing 10% fetal bovine serum, 5%
horse serum, 50 U/ml of penicillin and 50 U/ml of streptomycin in a 37 humidified incubator in an atmosphere of 95% air and 5% CO 2 .
Measurement of Intracellular Free Ca

2+
Concentrations. The changes in the intracellular free Ca 2+ concentration ([Ca 2+ ] i ) was monitored by the intensity of fura 2 fluorescence at 37
by spectrofluorometer (Hitachi, F-2000) , as described previously (Nakahata et al., 1994) .
PC12 cells cultured on a 150 mm dish were collected by gentle pipetting, and were washed twice with modified Tyrode solution (composition, mM: NaCl 137, KCl 2.7, MgCl 2 1.0, CaCl 2 0.18, HEPES 20, glucose 5.6, pH 7.4). After centrifuged at 250 g for 2 min, cells
This article has not been copyedited and formatted. The final version may differ from this version. Tyrode solution (pH 7.4) containing 10 mM LiCl and 2 mM EGTA for 6 min after cells were washed twice with the solution. Then cells were incubated with drugs for 6 min, and they were further incubated with 100 µM UTP for additional 6 min. The reaction was terminated by addition of equal volume of 10% trichloroacetic acid (TCA). The TCA extract was centrifuged at 1800 g for 5 min, and the supernatant was washed three times with diethyl ether. Total inositol phosphates were separated by an anion-exchange column (AG 1X-8),
and counted by liquid scintillation counting. After washing twice with the ice-cold solution, cells were centrifuged at 250 g for 2 min and the pellet was solubilized in 1 ml of lysis buffer containing 50 mM Tris-HCl, 50 mM NaCl, 0.1% Triton X-100, 5 mM EDTA, 1.0 mM Na 3 VO 4 , 5.0 mM Na 4 P 2 O 7 , 1.0 mM PMSF, 10 µg/ml aprotinin and 10 µg/ml leupeptin/antipain (pH 7.6). The lysates were sonicated on ice and were incubated at 4 for 1 h with frequent agitation. Lysates (1 ml) were mixed with 3 ml of 60% sucrose in STE buffer (50 mM Tris-HCl, 50 mM NaCl, 5 mM EDTA and 1.0 mM Na 3 VO 4 , pH 7.6) in a centrifuge tube and they were overlaid with 4 ml of 35% sucrose and 4 ml of 5% sucrose. Centrifugation was performed at 200,000 g for 16 h at 4 with a Beckman SW41Ti rotor. Fractions of 1.0 ml were collected from the top of the gradients (Yamashita et al., 2001 ).
Immunoblotting. Each fraction was solubilized in Laemmli sample buffer (75 mM Tris-HCl, 2% SDS, 10% glycerol, 3% 2-mercaptoethanol, 0.003% bromophenol blue), and resolved by SDS/PAGE on 11% acrylamide gels. Separated proteins were transferred to polyvinylidene difluoride membrane (Millipore, Bedford, MA) by a semi-dry blot apparatus. The blots were immersed in 3% skim milk in Tris-buffered saline (pH 7.4) containing 0.1% Tween 20
(TBST) for 2 h at room temperature. The blots were washed with TBST and incubated with the appropriate primary antibody for 2 h at room temperature. Then the blots were washed with TBST and incubated with a horseradish peroxidase-conjugated secondary antibody for 2 h. After washing, immnoreactive proteins were visualized with an enhanced chemiluminescence system. ]mastoparan was activated at 280 nm and the emission spectrum was recorded.
Background intensities of samples were subtracted from each sample spectrum. for 15 min, and they were incubated with 10 µM mastoparan for additional 15 min.
Measurement of
Reactions were terminated by cooling the tubes on ice. After samples were centrifuged at 1200 g for 2 min, 10 µl of supernatants were used for determination of released LDH.
Data analysis.
The results were expressed as mean ± S.E.M., and the statistical difference of the values was determined by one-way analysis of variance with Dunnett test for multiple comparisons.
This article has not been copyedited and formatted. The final version may differ from this version. ] i elevation was concentration-dependent (Fig. 1B) . The inhibition curve for mastoparan is similar to that for mastoparan on carbachol-induced increase in [Ca 2+ ] i in 1321N1 cells (Nakahata et al., 1994) . In addition, mastoparan inhibited UTP-induced phosphoinositide hydrolysis in a concentration-dependent manner ( Fig. 2A) channel. Next, we examined whether PTX affected mastoparan-induced inhibition of the phosphoinositide hydrolysis ( Fig. 2B ), because P2Y 2 receptor has been reported to be coupled to not only Gα q but also Gα i (Erb et al., 2001) . Although UTP-induced phosphoinositide hydrolysis was decreased by PTX, mastoparan-induced inhibition of phosphoinositide hydrolysis was not attenuated by PTX. On the other hand, MβCD, a reagent extracting cholesterol from plasma membrane to disrupt lipid rafts, concentrationdependently inhibited UTP-induced phosphoinositide hydrolysis as well as mastoparan did (Fig. 2C ).
Mastoparan Induced Change in the Localization of Signaling Molecules in Cell
Membranes. To evaluate whether mastoparan changes the localization of signaling molecules
This article has not been copyedited and formatted. The final version may differ from this version. in lipid rafts, detergent-treated PC12 cell lysates were separated into fractions by a sucrose density gradient centrifugation and signaling molecules in the fractions were determined by immunoblotting (Fig. 3A) . Flotillin-1 and GM1, lipid raft marker molecules, were mainly detected in DRM fractions (4-5 fractions) in control cells without mastoparan treatment.
Gα q/11 was detected abundantly in DRM fractions in control cells. The treatment of cells with mastoparan resulted in a decrease in Gα q/11 level in DRMs. On the other hand, the distribution of Gα q/11 was not changed by UTP treatment (Fig. 3B ). Mastoparan reduced the distribution level of not only Gα q/11 but also Gβ, Gα s and Gα i in DRMs, showing that mastoparan may affect lipid rafts followed by changing the distribution of signaling molecules in lipid rafts. In contrast, GM1 did not change their distributions in response to mastoparan.
The analysis of signaling molecules in DRMs suggests that mastoparan may interact with lipid rafts. We speculated that gangliosides, components of lipid rafts, have an important role as a binding site of mastoparan in lipid rafts because mastoparan has positive charges due to three Lys residues. Negative charges of sialic acid residues of gangliosides contribute to the membrane electric charge, causing the interaction with a variety of positively charged substances (Millar et al., 1999) . Therefore, we investigated the interaction of mastoparan with gangliosides by determining whether exogenously added gangliosides attenuate the effect of mastoparan. PC12 cells were incubated with 30 µM mastoparan in the presence of 300 µg/ml ganglioside mixture in modified Tyrode solution for 1 h and they were
signaling molecules level in DRMs was attenuated by addition of ganglioside mixture ( Fig.   3A ).
In order to examine whether the decrease in Gα q/11 level in lipid rafts comes from the This article has not been copyedited and formatted. The final version may differ from this version. release of Gα q/11 from lipid rafts to cytosol, we examined whether Gα q/11 was released from membranes when membrane preparations were treated with mastoparan ( Fig. 4) . Gα q/11 was hardly released from membrane preparations without drug, but it was markedly released by treatment with mastoparan. Furthermore, the release of Gα q/11 by mastoparan was attenuated by the incubation in the presence of ganglioside mixture.
On the other hand, mastoparan affected not only functional proteins in lipid rafts but also the content of cholesterol. Cholesterol level in 5 fraction was decreased from 83 ± 0.48 µg/fraction to 35 ± 0.77 µg/fraction by treatment with mastoparan ( Fig. 5) , and it was attennuated by the preincubation of cells with ganglioside mixture. These data show that mastoparan interacts with gangliosides in lipid rafts and decreases some signaling molecules in lipid rafts by releasing them from membranes to cytosol or by changing the localization of them in plasma membranes.
Inhibition of UTP-induced Phosphoinositide Hydrolysis by Mastoparan is Attenuated by
the Preincubation of Neuraminidase. Next, we investigated whether exogeneously added sialic acid, gangliosides or neuraminidase, which released sialic acid from gangliosides, attenuated the inhibitory effect of mastoparan on UTP-induced phosphoinositide hydrolysis.
PC12 cells labeled with [
3 H]inositol were preincubated for 6 min with 10 µM sialic acid or 20 µg/ml ganglioside mixtures or for 20 min with 1 mU neuraminidase, then they were incubated with 10 µM mastoparan for 6 min, followed by the incubation with 100 µM UTP for additional 6 min ( On the other hand, the changes of the fluorescence intensity were not observed when sialic acids were added (Fig. 7B) . These results show that mastoparan binds specifically to gangliosides.
Mastoparan-induced Cytotoxicity was Inhibited by Exogenous Addition of Gangliosides,
especially GD1b and GT1b. The cytotoxicity of mastoparan was monitored by measuring LDH activity. Mastoparan caused cytotoxicity at the concentrations over 10 µM, and over 60% of cells were dead at a concentration of 30 µM (Fig. 8A) . The cytotoxicitiy was suppressed by treatment of the cells with neuraminidase in a concentration-dependent manner (Fig. 8B) . Similarly, the preincubation of the cells with ganglioside mixture resulted in the attenuation of mastoparan-induced cytotoxicity (Fig. 9A ). On the other hand, the mastoparan toxicity was not inhibited by treatment with sialic acid at the concentration up to 100 µM. In order to examine the difference in ganglioside species, several gangliosides (0.3-10 µM) were used to determine the blockade of mastoparan-induced cytotoxicity ( 
Discussion
The present study demonstrated that mastoparan changed the localization of signaling molecules, such as Gα q/11 and Gβ from lipid rafts to non-lipid rafts or cytosol in PC12 cells, and that this change might result in the inhibition of Gα q/11 -mediated phosphoinositide hydrolysis ( Fig. 2 and 3A) . Furthermore, it was revealed that Gα q/11 was released from plasma membrane by mastoparan in membrane preparations (Fig. 4) . Bhatnagar et al. (2004) showed that G q -coupled P2Y signaling were decreased in caveolin A modification of proteins by the covalent attachment of myristic acid and palmitic acid is one of the mechanisms that proteins accumulate in lipid rafts (Melkonian et al., 1999) .
It is
This article has not been copyedited and formatted. The final version may differ from this version. (Brown, 1998; Rietveld and Simons, 1998) . The treatment of cells with mastoparan resulted in the change of the localization of some proteins, such as Gα q/11 and Gβ with decreasing the content of cholesterol in lipid rafts ( Fig. 3A and 5) ,
suggesting that the change in the component of lipid rafts by mastoparan may cause the decrease of hydrophobic interactions within lipid raft molecules followed by the change in the localization of signaling molecules. The influence of mastoparan on the localization of molecules in lipid rafts was different in each molecule. This difference might possibly due to the manner of tropism of each protein to lipid rafts. Hughes et al. (2001) showed that membrane-associated Gα q did not change the distribution upon activation. Actually, the stimulation of P2Y 2 receptor by UTP resulted in no influence to Gα q distribution (Fig. 3B) .
Although we have shown that mastoparan releases Gα q from lipid rafts in the plasma membranes, it remains unknown what kinds of mechanisms are involved in the release.
Thus, since we do not know the exact mechanism that mastoparan changes the localization of these molecules so far, more detailed study is required for the elucidation of this mechanism.
Gangliosides are glycolipids composed of sphingolipid ceramide and oligosaccharide with one or more sialic acid residues, and they are highly expressed in membranes of neuronal cells of brain. Gangliosides are also known to participate in various physiological functions, such as cell proliferation, differentiation and signal transduction (Mitsuda et al., 2002) .
Because the pretreatment of cells with gangliosides or neuraminidase attenuated the cytotoxicity of mastoparan in the present study, it is suggested that mastoparan initially binds This article has not been copyedited and formatted. The final version may differ from this version. to gangliosides in lipid rafts, and then causes a variety of actions ( Fig. 7 and Fig. 8 ).
Interestingly, it was previously reported that histamine release induced by mastoparan in mast cells was inhibited by the pretreatment of cells with neuraminidase (Mousli et al., 1989) , although it is believed that mastoparan-induced histamine release is mediated via pertussis toxin-sensitive G protein (G i/o ). Since MβCD causes cytotoxicity through removing cholesterol from plasma membranes, mastoparan-induced cytotoxicity might be also due to a decrease of cholesterol in lipid rafts. Cholesterol is important in the formation of lipid rafts, and the decrease of cholesterol in lipid rafts is one of the reasons for mastoparan-induced change in the localization of signaling molecules. Although mastoparan caused cytotoxicity and inhibition of PI hydrolysis through separate mechanisms, the binding of mastoparan to gangliosides might cause a decrease of cholesterol in lipid rafts, resulting in the cytotoxicity as well as the inhibition of PI hydrolysis through the release of Gα q protein.
Mastoparan is an amphipathic peptide with four positive charges, three Lys residues and a terminal amino group. When mastoparan is bound to a phospholipid bilayer, the Cterminal 12 residues of mastoparan form α-helix structure with three Lys residues positive charged hydrophilic side chain located on one side and with hydrophobic side chain on the other side (Wakamatsu et al., 1992) . Taken in the light of the conformation of mastoparan in lipid bilayers, it is suggested that the electrostatic interaction between Lys residue side of mastoparan and gangliosides on cell surface is the first step as cell recognition, and then the hydrophobic side enters into phospholipid bilayer. The analysis of mastoparan analogues showed that the change of amphiphilicity also changed the activity of GDP/GTP exchange activation (Jones and Howl, 2004) , showing that amphipathic character of mastoparan may be essential for binding to cell membranes by means of the mechanism described above.
Furtheremore, we examined the difference in inhibitory effects of various kinds of
This article has not been copyedited and formatted. The final version may differ from this version. gangliosides on cytotoxicity of mastoparan. The order of inhibitory potency of gangliosides was GT1b GD1b > GD1a > GM1 GQ1b (Fig. 8B) . Asialo-GM1 and sialic acid were inactive. GQ1b, which has 4 sialic acid residues, showed a lower inhibitory potency than other gangliosides that have 1-3 sialic acid residues, suggesting that the number of sialic acid of gangliosides does not correlate with the inhibitory potency of gangliosides to mastoparan action. Gangliosides have the structure of ceramide-Glc-Gal-GalNAc-Gal, and sialic acid binds to Gal, which is second or fourth sugar residue from ceramide.
Compared the binding manners of sialic acid residues to ceramide with the inhibitory potency, the increased number of sialic acids that bind to second Gal are likely to enhance the inhibitory potency, whereas the excessive number of sialic acids bound to fourth Gal may decline the inhibitory potency. Thus, it is possible that Lys residue side of mastoparan interacts with sialic acids bound to second Gal. If a number of sialic acids that bind to second Gal are increased, the electrostatic interaction between mastoparan and gangliosides is increased and mastoparan binds strongly to gangliosides. On the other hand, when a number of sialic acids that bind to fourth Gal are increased, mastoparan binds to gangliosides weakly because of the repulsion between sialic acid residues (hydrophilicity) and hydrophobic side of mastoparan. To prove this hypothesis, further study is required using several kinds of gangliosides. We examined mastoparan-induced cell cytotoxicity in not only PC12 cells but also 1321N1 human astrocytoma cells, showing that the cytotoxic sensitivity of 1321N1 cells to mastoparan is about 1/3 of that of PC12 cells (Sugama et al., unpublished observations).
It is necessary to examine the composition of gangliosides between PC12 cells and 1321N1 cells, for clarifying the reason of the different sensitivity of mastoparan to both cell lines.
Since both of mastoparan effects, the inhibition of G q -signaling and the cytotoxicity, are attenuated by gangliosides and neuraminidase, it is interesting to clarify the molecular This article has not been copyedited and formatted. The final version may differ from this version. mechanisms of these effects in the future.
In conclusion, mastoparan initially binds to sialic acids of gangliosides in lipid rafts, and then it changes the components of lipid rafts followed by the decrease of some signaling molecules in lipid rafts, such as Gα q/11 and Gβ by changing their localization in lipid rafts.
By such a mechanism, it is predicted that mastoparan inhibits Gα q -mediated phosphoinositide hydrolysis. This is the first demonstration of the lipid raft-mediated mechanism of mastoparan action.
This article has not been copyedited and formatted. The final version may differ from this version. experiments. * Significant difference from control (P < 0.05). ** Significant difference between MP alone and MP plus ganglioside mixtures (P < 0.05). were incubated with ( ) or without ( ) 10 µM MP for 6 min, followed by the incubation with 100 µM UTP for 6 min. The data are mean ± S.E. of six experiments. * Significant difference from without neuraminidase (P < 0.05). The data are mean ± S.E. of six experiments. * Significant difference between mastoparan alone and mastoparan plus neuraminidase (P < 0.05). 
